Tone mix
Week by week 50 weeks
Share of Geron Corp's 164 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 29, 2025 · tone -100British & American swings to interim loss, NAV falls on Geron slump-108
- Week of Oct 27, 2025 · tone +100Geron Corporation (GERN) Stock Analysis: Exploring A Potential 192% Upside For Healthcare Investors+100
- Week of Nov 24, 2025 · tone +100Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans+93
- Week of Mar 2, 2026 · tone +100Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success+80
- Week of Jan 12, 2026 · tone +97Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth+79
- Week of Feb 16, 2026 · tone -48Top 2 Industrials Stocks That Are Ticking Portfolio Bombs - FedEx (NYSE:FDX), Geron (NASDAQ:GERN)-74
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Geron Corp in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 9 | -34 |
| Last 30 sessions | 16 | -28 |
| Last 90 sessions | 38 | -6 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, November 5, 2026
3 headlines, average tone +30: 1 positive, 2 neutral and 0 negative. Showing all 3.
- seekingalpha.com · 1 outletGeron outlines $220M-$240M 2026 RYTELO net revenue outlook while initiating Germany launch by year-end (NASDAQ:GERN)Positive
- www.fool.com · 1 outletGeron: 3 Key Takeaways for Long-Term InvestorsNeutral
- www.fool.com · 1 outletGeron Corp (GERN) Q3 2026 Earnings Call TranscriptNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Geron outlines $220M-$240M 2026 RYTELO net revenue outlook while initiating Germany launch by year-end (NASDAQ:GERN) | seekingalpha.com | 1 | Positive |
| Geron: 3 Key Takeaways for Long-Term Investors | www.fool.com | 1 | Neutral |
| Geron Corp (GERN) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletGeron Corporation Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNeutral
- www.themarketsdaily.com · 1 outletReviewing Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights | www.manilatimes.net | 1 | Neutral |
| Reviewing Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
1 headline, average tone -99: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.medicaldaily.com · 1 outletGeron Ends Phase 3 Imetelstat Myelofibrosis Trial After Independent Monitors Say Survival Goal Is Unlikely to Be MetNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Geron Ends Phase 3 Imetelstat Myelofibrosis Trial After Independent Monitors Say Survival Goal Is Unlikely to Be Met | www.medicaldaily.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 29, 2026
3 headlines, average tone -98: 0 positive, 0 neutral and 3 negative. Showing all 3.
- www.medscape.com · 1 outletGeron Discontinues Late-stage Trial Of Blood Cancer Drug, Shares PlungeNegative
- seekingalpha.com · 1 outletGeron stock drops after halting Rytelo trial (GERN:NASDAQ)Negative
- www.rttnews.com · 1 outletGeron Discontinues Phase 3 IMpactMF Trial Of Imetelstat In Myelofibrosis; Data Analysis PlannedNegative
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Geron Discontinues Late-stage Trial Of Blood Cancer Drug, Shares Plunge | www.medscape.com | 1 | Negative |
| Geron stock drops after halting Rytelo trial (GERN:NASDAQ) | seekingalpha.com | 1 | Negative |
| Geron Discontinues Phase 3 IMpactMF Trial Of Imetelstat In Myelofibrosis; Data Analysis Planned | www.rttnews.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletGeron (NASDAQ:GERN) vs. Absci (NASDAQ:ABSI) Critical ReviewNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Geron (NASDAQ:GERN) vs. Absci (NASDAQ:ABSI) Critical Review | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Geron Corp, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.